Inspira Technologies’ Stock Jumps Following First U.S. Patent for Blood Oxygenation System

New York, February 14, 2024 - PRISM MarketView - Inspira Technologies (Nasdaq: IINN), a pioneering medical technology company aiming to advance beyond traditional mechanical ventilators, has been granted the first-ever U.S. Patent for an orbiting blood oxygenation delivery system. This system is a central feature of the innovative INSPIRA™ ART500 device, marking a significant leap in blood oxygenation technology. The patented system, known as VORTX™, is designed to oxygenate blood in a way that mimics the natural, laminar flow of blood vessels, avoiding the damage caused by the turbulent flow in current fiber-based oxygenators.

The traditional fiber technologies used for oxygenating blood often result in significant damage to blood cells due to friction and shear forces. This can lead to a range of complications, including the breakdown of red blood cells, damage to white blood cells, and activation of the body’s inflammatory and immune responses. The VORTX™ system, with its 16 claims of novelty, aims to transform this scenario by providing a more gentle and efficient method of blood oxygenation.

The INSPIRA ART500 device itself is designed to support patients’ breathing while they are awake, continuously monitoring blood parameters and delivering the required volume of oxygen directly into the bloodstream. Equipped with the HYLA blood sensor, the device is also capable of real-time monitoring of the patient’s condition, offering valuable data to assist physicians in decision-making.

The approval of this patent marks a significant step for Inspira Technologies in their efforts to innovate within the $19 billion mechanical ventilation market through the development of advanced solutions.

Shares of Inspira Technologies surged 27%, making it the leading intraday gainer in the PRISM Emerging MedDevice Index

Inspira™ Technologies is an innovative medical technology company in the respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology (INSPIRA ART), designed to rebalance patient oxygen saturation levels. This technology potentially allows patients to remain awake during treatment while reducing the need for highly invasive, risky, and costly mechanical ventilation systems that require intubation and medically induced coma. The Company’s products have not yet been tested or used in humans and has not been approved by any regulatory entity.

Media Contact
Company Name: Prism MarketView
Email: info@prismmarketview.com
Phone: 646-863-6341
Website: https://prismmarketview.com